InsidersTradesSigma
Follow the Biolife Solutions INC share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Biolife Solutions INC has logged 686 public disclosures. Market capitalisation: €1.4bn. The latest transaction was disclosed on 21 July 2026 (Retenue fiscale). Among the most active insiders: Mathew Aby J.. The full history is openly available.
686
Insider Decl.
n/a
Thresholds
€12m
4 ops.
Buy Volume
€101m
418 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Biolife Solutions INC Strong Buy (bullish), based on 9 analysts. Average price target: US$32.11.
41Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 17,448 of 29,062 companies
45.9
score / 100
Value35
Quality57
FCF yld0.0%
Earn yld-0.3%
EV/EBITDA·
ROE13%
Gross mgn65%
Net mgn-4.8%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 July 2026
Declarations686 total
275 shares@ US$29.150.0006% mcap9.0% of flowCommon StockSEC:0001628280-26-049086:0
293 shares@ US$27.790.0006% mcap0.4% of flowCommon StockSEC:0001628280-26-048052:0
516 shares@ US$27.790.0010% mcap0.7% of flowCommon StockSEC:0001628280-26-048053:0
844 shares@ US$27.790.0017% mcap1.1% of flowCommon StockSEC:0001628280-26-048054:0
564 sharesCommon StockSEC:0001628280-26-044694:0
937 sharesCommon StockSEC:0001628280-26-044695:0
2,775 sharesCommon StockSEC:0001628280-26-044696:0
420 sharesCommon StockSEC:0001628280-26-044698:0
470 sharesCommon StockSEC:0001628280-26-044699:0
627 sharesCommon StockSEC:0001628280-26-042284:0
356 sharesCommon StockSEC:0001628280-26-042285:0
1,026 sharesCommon StockSEC:0001628280-26-042286:0
300,000 shares@ US$22.650.50% mcap15.2% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:0
250,000 shares@ US$23.700.44% mcap13.2% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:1
650,000 shares@ US$23.701.14% mcap34.4% of flowCommon Stock, par value $0.001 per shareSEC:0000919574-26-003646:2
844 shares@ US$19.271.3% of flowCommon StockSEC:0001628280-26-024765:0
293 shares@ US$19.270.3% of flowCommon StockSEC:0001628280-26-024766:0
515 shares@ US$19.270.4% of flowCommon StockSEC:0001628280-26-024767:0
2,577 shares@ US$19.170.0037% mcap3.1% of flowCommon StockSEC:0001628280-26-022501:0
11,101 shares@ US$19.124.3% of flowCommon StockSEC:0001628280-26-020581:0
1,879 shares@ US$19.122.1% of flowCommon StockSEC:0001628280-26-020580:0
1,681 shares@ US$19.1250.7% of flowCommon StockSEC:0001628280-26-020579:0
3,749 shares@ US$19.125.4% of flowCommon StockSEC:0001628280-26-020578:0
931 shares@ US$19.121.8% of flowCommon StockSEC:0001628280-26-020577:0
1,907 shares@ US$19.122.8% of flowCommon StockSEC:0001628280-26-020576:0
25 of 686 declarations
关于 Biolife Solutions INC
BioLife Solutions Inc. 是一家美国公司，在纳斯达克上市，股票代码为BLFS。该公司专注于细胞和基因治疗（CGT）行业的生物生产工具和服务，重点是保护细胞完整性、提高生产重现性以及降低存储、运输和处理工作流程中的风险。实际上，BioLife 销售专门产品，供生物制药客户在CGT供应链的关键步骤中保持敏感生物材料的活力。其当前的宣传信息和备案文件始终将该公司描述为CGT市场细胞处理工具和服务的开发商和供应商。([biolifesolutions.com](https://www.biolifesolutions.com/?utm_source=openai)) BioLife 拥有悠久的运营历史，并随着时间的推移从一家专注于保存产品的公司发展成为一个服务于先进疗法的更广泛的生物生产平台。该公司总部位于华盛顿州博塞尔，并在那里设有制造、研发、营销和行政职能部门。这一布局为 BioLife 在美国生物技术走廊提供了强大的运营基础，同时服务于远远超出国内市场的客户群。([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026012294/blfs-20251231.htm?utm_source=openai)) 其核心业务线包括生物保存培养基、细胞培养优化产品、封闭系统灌装和储存解决方案以及相关的运输和处理技术。知名产品系列包括 CryoStor 和 HypoThermosol，以及旨在保持细胞质量、降低污染暴露和支持无菌生产的补充解决方案。BioLife 的战略吸引力在于它不作为一家大型制药制造商参与竞争；相反，它在CGT生态系统中占据了一个专业的赋能层，在这个领域，流程可靠性和监管验证比单纯的规模更重要。([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/a2025blfsinvestorpresent.htm?utm_source=openai)) 从竞争角度来看，BioLife 似乎已成为利基市场的领导者。其产品嵌入到要求严苛的CGT工作流程中，投资者材料表明其在临床试验和已批准疗法中取得了显著进展。这种嵌入式使用可以建立牢固的客户关系、更高的转换成本，并在制造复杂性仍然是主要瓶颈的行业中发挥防御性作用。因此，该公司的市场地位最好理解为先进疗法价值链的高价值基础设施供应商，而不是传统的生命科学供应商。([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/a2025blfsinvestorpresent.htm?utm_source=openai)) 最近的发展强化了向更高质量收入和盈利能力的战略转变。BioLife 于2026年2月26日公布了2025年全年业绩，随后于2026年5月7日公布了2026年第一季度业绩。该公司还发布了2026年业绩指引，并继续强调其核心CGT业务的增长。对于关注内幕交易和SEC Form 4备案文件的投资者而言，BLFS 结合了创新驱动的商业模式、对长期CGT主题的敞口以及在美国纳斯达克上市的地位，并在近期投资组合调整后，拥有一个更专注、更注重利润的投资组合。([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/blfsq42025earningsrelease.htm?utm_source=openai))
